4.6 Review

Epidemiological and clinical features, therapeutic strategies and outcomes in patients with hyperhaemolysis: A systematic review

Journal

BRITISH JOURNAL OF HAEMATOLOGY
Volume 201, Issue 6, Pages 1025-1032

Publisher

WILEY
DOI: 10.1111/bjh.18825

Keywords

blood transfusion; clinical transfusion medicine; haemolytic anaemia; hyperhemolysis; immunohaematology; sickle cell disease

Categories

Ask authors/readers for more resources

Hyperhaemolysis syndrome (HHS), a severe form of delayed haemolytic transfusion reaction, often occurs in patients with sickle cell disease (SCD) and involves destruction of both donor and recipient red blood cells (RBCs). This systematic review identified 51 patients with HHS, characterized their epidemiological and immunohaematological characteristics, and found that additional transfused RBCs may be associated with a longer time-to-recovery.
Hyperhaemolysis syndrome (HHS), a severe form of delayed haemolytic transfusion reaction most commonly described in patients with sickle cell disease (SCD), involves destruction of both donor and recipient red blood cells (RBCs). As the epidemiology and underlying pathophysiology have yet to be definitively elucidated, recognition can be challenging. We systematically reviewed PubMed and EMBASE to identify all cases of post-transfusion hyperhaemolysis and characterized the epidemiological, clinical and immunohaematological characteristics and treatments of HHS. We identified 51 patients (33 females and 18 males), including 31 patients with SCD (HbSS, HbSC and HbS/beta-thalassaemia). The median haemoglobin nadir (3.9 g/dL) occurred a median of 10 days post-transfusion. 32.6% and 45.7% of patients had a negative indirect anti-globulin test and a negative direct anti-globulin test, respectively. The most common therapies included corticosteroids and intravenous immune globulin. 66.0% of patients received >= 1 supportive transfusion, which was associated with a longer median hospital stay/time to recovery (23 days vs. 15 days; p = 0.015) compared to no supportive transfusion. These findings illustrate that HHS that often results in marked anaemia 10 days post-transfusion is not restricted to patients with haemoglobinopathies, and additional transfused RBCs may be associated with a longer time-to-recovery.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available